PTC Therapeutics Announces Key Participation in Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT), a leading global biopharmaceutical firm, is set to engage with investors at two prestigious healthcare conferences in early March 2025. The company's focus lies in discovering, developing, and commercializing innovative therapies for rare disorders, positioning it as a vital player in the biopharmaceutical landscape.

PTC Therapeutics executives will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. ET. This conference is an excellent opportunity for PTC to highlight its advancements and strategic directions to a broad audience of investors and healthcare professionals.

Shortly after the TD Cowen event, PTC will take the stage at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025, at 12:30 p.m. ET. This conference is known for attracting high-profile participants and offers PTC an additional platform to showcase its innovative pipeline and therapeutic developments.

Both presentations will be accessible via live webcast on the Events and Presentations page under the Investor section of PTC Therapeutics' official website. Interested parties are encouraged to log in several minutes before the scheduled start times to ensure seamless access. Following the live events, the webcasts will be archived for 30 days, allowing investors and analysts who cannot attend live to catch up on the discussions.

PTC Therapeutics is recognized for its commitment to innovation in the biopharmaceutical sector. The company focuses on developing clinically differentiated medicines that address the needs of children and adults affected by rare disorders. PTC's robust and diversified pipeline is supported by its ability to identify new therapies and globally commercialize them effectively, which is a critical driving force behind its investment strategy.

For investors seeking more information, PTC Therapeutics encourages visits to their official website at www.ptcbio.com and following their social media accounts on platforms like Facebook, Instagram, LinkedIn, and X. This digital engagement ensures stakeholders remain informed about the latest company updates and developments in their therapeutic offerings.

For further inquiries, PTC Therapeutics has designated contacts:

Investors:

Ellen Cavaleri

Phone: +1 (615) 618-6228

Media:

Jeanine Clemente

Phone: +1 (908) 912-9406

PTC Therapeutics' participation in these upcoming investor conferences underscores its ongoing commitment to transparency and investor engagement. As the company continues to advance its innovative pipeline, the discussions at these conferences will likely provide valuable insights into its strategic direction and market potential. Investors and healthcare professionals alike will be keenly watching these events for updates that could shape the future of rare disease therapies.